My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 11 776 / https://doi.org/10.3332/ecancer.2017.776

Clinical Study

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

Background: EGFR mutation subtype is a recognised factor impacting outcomes of patients receiving oral tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC). Evidence for the effect of this factor on outcomes in patients receiving pemetrexed is limited.

Methods: We completed a study comparing pemetrexed–platinum combination versus oral TKI in EGFR mutation-positive patients in lung cancer. We analysed the impact of EGFR mutation subtype, specifically, exon 19 and 21 on the PFS and OS of patients treated with pemetrexed (500 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) as first-line therapy. Patients underwent axial imaging for response assessment on D42, D84, D126 and subsequently every two months till progression. Patients post-progression were treated with gefitinib.

Results: Fifty-one patients (36%) had exon 21 mutation, while 92 patients (64%) had exon 19 mutation. Response rates in evaluable patients was 47.7% in exon 19 patients (41 patients, n = 86) and 42.9 % in exon 21 patients (18 patients, n = 42). There was a significant increase in median overall survival for patients with exon 19 mutations (24.5 months, 95% CI: 21.3–27.7 months ) over the exon 21-mutated patients (18.1 months, 95% Cl: 13.5–22.6 months, p = 0.002). This differential impact was due to second-line gefitinib having a differential outcome on these mutations.

Conclusion: Pemetrexed-based chemotherapy does not have a differential impact on exon 19- or exon 21-mutated patients. However, second-line treatment with gefitinib has a favourable response and outcome in exon 19-mutated patients.

Keywords: EGFR mutation, NSCLC, exon 19, pemetrexed, exon 21, gefitinib, prognosis

Loading Article Metrics ... Please wait

Related articles

Case Report: Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus

Abstract | Full Article | PDF Published: 14 Feb 2018 / https://doi.org/10.3332/ecancer.2018.811

Conference Report: United against cancer: prevention to end-of-life care—highlights from the Uganda Cancer Institute–Palliative Care Association of Uganda Joint International Conference on Cancer and Palliative Care and the 7th Palliative Care Conference, 24–25 August 2017, Kampala, Uganda

Abstract | Full Article | PDF Published: 14 Dec 2017 / https://doi.org/10.3332/ecancer.2017.790

Special Issue: Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come

Abstract | Full Article | PDF Published: 30 Nov 2017 / https://doi.org/10.3332/ecancer.2017.787

Clinical Study: Prognostic value of a patient-reported functional score versus physician-reported Karnofsky Performance Status Score in brain metastases

Abstract | Full Article | PDF Published: 10 Nov 2017 / https://doi.org/10.3332/ecancer.2017.779

Short Communication: Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines

Abstract | Full Article | PDF Published: 04 Sep 2017 / https://doi.org/10.3332/ecancer.2017.764



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence